Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

類似資料

• Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
  著者:: Postow, Michael A, 等
  出版事項: (2014)
• Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer
  著者:: Rajan, Arun, 等
  出版事項: (2014)
• Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
  著者:: Gettinger, Scott N., 等
  出版事項: (2015)
• Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma
  著者:: Gyorki, David E., 等
  出版事項: (2013)
• Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients
  著者:: Wolchok, Jedd D., 等
  出版事項: (2013)